(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Science is best communicated through identity and culture – how researchers are ensuring STEM serves their communities - 2The Extraordinary Excursion of Dental Embed Innovation
- 3Manual for Savvy Home Lighting Framework: Lights up Your Space
- 4Pacific voyagers’ remarkable environmental knowledge allowed for long-distance navigation without Western technology
- 5The Appearance of Experience: Embracing the Reduced Portage Horse
- At least 30 killed in attack on Nigeria village
- How a Snake That Eats Cobras Redefined the Meaning of ‘King’
- UN rights chief: Israel's new Gaza aid agency rules 'outrageous'
- New hybrid mpox strain discovered in UK after US reports local spread
- From Loner to Force to be reckoned with: Individual Accounts of Change
- The Most Paramount Crossroads in Olympic History
- What did the gov’t approve for Israel’s 2026 state budget?
- Understanding Preschool Projects: An Extensive Aide
- Embrace Effortlessness: Moderation and Cleaning up Tips
